Ozempic (semaglutide) may impact kidney health in certain people, especially those with diabetes. Learn more about what the ...

Nov. 6, 2024 – The FDA has updated the labels for all GLP-1 weight loss drugs with a warning about pulmonary aspiration ...

News Do Certain Diabetes Drugs Increase the Risk of Acute Kidney Injury in Patients Taking Anti-Cancer Therapies? Glucagon-like peptide-1-receptor agonists (GLP-1RA) are medicatio ...

The Impact of New Weight Loss Drugs on Dietetics By Carrie Dennett, MPH, RDN Today’s Dietitian Vol. 26 No. 9 P. 14 What’s changed for weight-inclusive and weight management dietitians?

Results from a retrospective cohort study show lower all-cause mortality and fewer hospitalizations and intestinal ...

Weight loss interventions are associated with improvement in some features of polycystic ovary syndrome (PCOS).

In a Q&A, an FDA spokesperson discusses efforts to reduce misinformation about biosimilars through education, the agency’s ...

Among privately insured patients, there was a doubling in the use of GLP-1 RAs as antiobesity treatment from 2022 to 2023, with a simultaneous 25.6% decrease in the rate of metabolic bariatric surgery ...

SGLT2 inhibitors and GLP-1 receptor agonists exhibit renoprotective effects in patients with CKD with and without diabetes.

Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) ...

Novo Nordisk on Wednesday reported third quarter earnings broadly in line with expectations and narrowed its 2024 full-year ...

Novo Nordisk on Wednesday reported third quarter earnings broadly in line with expectations and narrowed its 2024 full-year ...